PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis - PubMed (original) (raw)

PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis

Mark D Danese et al. Am J Kidney Dis. 2006 Jan.

Abstract

Background: Few investigations have described fracture risk and its relation to disorders in calcium (Ca), phosphorus (P), and parathyroid hormone (PTH) metabolism in the end-stage renal disease population.

Methods: Laboratory values for Ca, P, and PTH were obtained from Dialysis Morbidity and Mortality Study (DMMS) Waves 1 to 4. Additional data available from the US Renal Data System were used to determine the incidence and associated costs of hip, vertebral, and pelvic fractures in 9,007 patients with nonmissing laboratory values and Medicare as primary payor. Cox proportional hazards and Poisson models were used to analyze time to first fracture and numbers of fractures, respectively.

Results: There was no association between Ca or P values and risk for fracture; risks for vertebral and hip fractures and PTH concentrations were U shaped and weakly significant using Poisson regression (P = 0.03). The age- and sex-adjusted mortality rate after fracture was 2.7 times greater (580/1,000 person-years) than for general dialysis patients from the DMMS (217/1,000 person-years). Mean total episodic costs of hip, vertebral, and pelvic fractures were 20,810 dollars +/- 16,743 dollars (SD), 17,063 dollars +/- 26,201 dollars, and 14,475 dollars +/- 19,209 dollars, respectively.

Conclusion: Using data from the DMMS, there were no associations between Ca and P concentrations and risk for fracture. Risks for hip and vertebral fracture were associated weakly with PTH concentration, with the lowest risk observed around a PTH concentration of 300 pg/mL (ng/L). Fractures were associated with high subsequent mortality and costs. Prospective studies are needed to determine whether therapies that maintain PTH concentrations within or near the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative range will result in fewer complications of disordered mineral metabolism.

PubMed Disclaimer

Cited by

Cellular changes following direct vitamin D injection into the uraemia-induced hyperplastic parathyroid gland.
Shiizaki K, Hatamura I, Negi S, Nakazawa E, Tozawa R, Izawa S, Akizawa T, Kusano E. Shiizaki K, et al. NDT Plus. 2008 Aug;1(Suppl 3):iii42-iii48. doi: 10.1093/ndtplus/sfn095. NDT Plus. 2008. PMID: 25983973 Free PMC article.
Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis.
Fusaro M, D'Angelo A, Scalzo G, Gallieni M, Giannini S, Guglielmi G. Fusaro M, et al. J Endocrinol Invest. 2010 May;33(5):347-52. doi: 10.1007/BF03346598. J Endocrinol Invest. 2010. PMID: 20534970 Review.
Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.
Malluche HH, Mawad HW, Monier-Faugere MC. Malluche HH, et al. J Bone Miner Res. 2011 Jun;26(6):1368-76. doi: 10.1002/jbmr.309. J Bone Miner Res. 2011. PMID: 21611975 Free PMC article.
Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship.
Fusaro M, Crepaldi G, Maggi S, Galli F, D'Angelo A, Calò L, Giannini S, Miozzo D, Gallieni M. Fusaro M, et al. J Endocrinol Invest. 2011 Apr;34(4):317-23. doi: 10.1007/BF03347093. Epub 2010 Nov 16. J Endocrinol Invest. 2011. PMID: 21088475 Review.
Osteoporosis in patients with diabetes after kidney transplantation.
Gosmanova EO, Gosmanov AR. Gosmanova EO, et al. Rev Endocr Metab Disord. 2017 Mar;18(1):97-106. doi: 10.1007/s11154-016-9397-5. Rev Endocr Metab Disord. 2017. PMID: 27866309 Review.

PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis - PubMed (original) (raw)